MG
PSTX

Michael Gelband’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Michael Gelband’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-76,686
Closed -$245K – 2087
2024
Q1 		$245K Buy
+76,686
New +$256K ﹤0.01% 1310
2021
Q3 		– Sell
-15,200
Closed -$152K – 2760
2021
Q2 		$152K Buy
+15,200
New +$136K ﹤0.01% 2057

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Michael Gelband's PSTX Position: Q2 2024 in Review

Michael Gelband sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2024, closing a stake of 76,686 shares — an estimated $245K sold.

Michael Gelband first reported a position in PSTX in Q2 2021 and held it in 2 quarters. The position peaked at $245K in Q1 2024. 93 funds tracked by Wall St. Rank hold PSTX as of Q2 2024.

  • Michael Gelband reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Michael Gelband sold 76,686 Poseida Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $245K.
  • Michael Gelband first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Michael Gelband's Poseida Therapeutics, Inc. Common Stock position peaked at $245K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.